Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SNTI

Senti Biosciences Holdings Inc

Jun 08 • 04:00PM ET

0.9416

-0.0238 -2.47 %

Healthcare • Biotechnology • USA • Nano • NASD

Peers: APLM BRNS CRVO GRDX IGC LSTA NRSN PLRZ SER SKYE

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.92	Insider Own	74.19%	Shs Outstand	31.14M	Perf Week	-3.95%
Market Cap	29.33M	Forward P/E	-	EPS next Y	-0.95	Insider Trans	0.00%	Shs Float	8.04M	Perf Month	-4.42%
Enterprise Value	39.53M	PEG	-	EPS next Q	-0.29	Inst Own	10.92%	Short Float	8.07%	Perf Quarter	-3.20%
Income	-51.55M	P/S	733.25	EPS this Y	62.03%	Inst Trans	-0.25%	Short Ratio	3.58	Perf Half Y	-57.59%
Sales	0.04M	P/B	11.43	EPS next Y	8.36%	ROA	-85.19%	Short Interest	0.65M	Perf YTD	-9.46%
Book/sh	0.08	P/C	3.28	EPS next 5Y	24.71%	ROE	-255.03%	52W High	3.88 -75.76%	Perf Year	-75.48%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	50.33% 65.37%	ROIC	-325.94%	52W Low	0.77 22.26%	Perf 3Y	-90.68%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-82.75% -70.12%	Gross Margin	-8847.37%	Volatility	5.40% 6.84%	Perf 5Y	-99.06%
Dividend TTM	-	EV/Sales	988.25	EPS Y/Y TTM	82.28%	Oper. Margin	-154810.53%	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.04	Sales Y/Y TTM	-100.00%	Profit Margin	-135650.00%	RSI (14)	45.76	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.04	EPS Q/Q	90.33%	SMA20	-3.79%	Beta	2.07	Target Price	13.00
Payout	-	Debt/Eq	7.48	Sales Q/Q	-	SMA50	-2.11%	Rel Volume	0.58	Prev Close	0.97
Employees	39	LT Debt/Eq	5.18	Earnings	May 14 BMO	SMA200	-26.95%	Avg Volume	180.99K	Price	0.94
IPO	May 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	61.11% -	Trades		Volume	106,851	Change	-2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-25	Initiated	H.C. Wainwright	Buy	$12
Jun-06-25	Initiated	Laidlaw	Buy	$5
Oct-07-22	Initiated	Morgan Stanley	Equal-Weight	$7.50

May-14-26 08:45AM	Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase (GlobeNewswire) +8.00%
08:40AM	Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program (GlobeNewswire)
Apr-13-26 09:00AM	Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 (GlobeNewswire)
Apr-01-26 08:45AM	Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies (GlobeNewswire)
Mar-27-26 08:00AM	Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (GlobeNewswire) -10.36%
09:00AM	Loading…
Mar-23-26 09:00AM	Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference (GlobeNewswire)
Mar-03-26 09:05AM	Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
Feb-24-26 09:15AM	Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +7.08%
Feb-20-26 08:50AM	Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development (GlobeNewswire)
Feb-11-26 08:35AM	Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) (GlobeNewswire)
Feb-03-26 09:00AM	Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 (GlobeNewswire)
Jan-14-26 09:15AM	Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation (GlobeNewswire)
Jan-09-26 08:55AM	Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference (GlobeNewswire)
Dec-18-25 05:30PM	Senti Biosciences Announces New Employment Inducement Grants (GlobeNewswire)
Dec-09-25 07:00AM	Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire) -35.56%
07:00AM	Loading…
07:00AM	Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile (GlobeNewswire)
Dec-04-25 08:45AM	Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET (GlobeNewswire)
Nov-13-25 04:30PM	Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December (GlobeNewswire) -5.29% -10.06%
Nov-03-25 09:05AM	Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 (GlobeNewswire)
Oct-16-25 09:05AM	Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire) -5.63%
Oct-06-25 09:05AM	Senti Bio to Present at BioJapan (GlobeNewswire)
Sep-18-25 09:15AM	Senti Bio to Present at the MedInvest Biotech & Pharma Conference (GlobeNewswire)
Sep-02-25 09:05AM	Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 09:15AM	Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Aug-12-25 09:15AM	Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia (GlobeNewswire)
Aug-07-25 08:05AM	Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 (GlobeNewswire) -8.88%
Aug-05-25 08:30AM	Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia (GlobeNewswire)
Jul-22-25 08:45AM	Senti Biosciences Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-21-25 08:55AM	Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum (GlobeNewswire)
08:55AM	Loading…
Jul-18-25 08:55AM	Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors (GlobeNewswire)
Jun-30-25 09:15AM	Senti Bio Participates in Nasdaq Amplify Spotlight Series (GlobeNewswire)
Jun-24-25 08:45AM	Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference (GlobeNewswire)
Jun-18-25 07:00AM	Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia (GlobeNewswire) -17.99%
Jun-09-25 04:30PM	Senti Biosciences Announces New Employment Inducement Grants (GlobeNewswire) -18.75%
Jun-06-25 09:05AM	Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC (GlobeNewswire) +7.87%
May-22-25 04:05PM	Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire) -5.28%
08:30AM	Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 (GlobeNewswire)
May-08-25 08:35AM	Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 (GlobeNewswire)
May-06-25 04:35PM	Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development (GlobeNewswire)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
09:15AM	Senti Bio Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Apr-30-25 09:00AM	Senti Bio to Present at the Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-28-25 07:00AM	Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML (GlobeNewswire) -27.20%
Apr-24-25 08:35AM	Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET (GlobeNewswire) +9.93%
Apr-21-25 09:05AM	Senti Bio Participates in a Virtual Investor KOL Connect Segment (GlobeNewswire)
Apr-16-25 09:15AM	Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment (GlobeNewswire)
Apr-10-25 08:45AM	Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D. (GlobeNewswire) -7.99%
Apr-07-25 08:45AM	Senti Bio Joins Webull Corporate Connect Service Platform (GlobeNewswire)
Apr-03-25 09:00AM	Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -6.54%
Mar-20-25 04:01PM	Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights (GlobeNewswire)
Mar-13-25 04:01PM	Senti Bio Appoints Feng Hsiung to Board of Directors (GlobeNewswire) +8.72%
Feb-25-25 08:00AM	Senti Bio Strengthens Leadership Team with Strategic Hires (GlobeNewswire)
Jan-06-25 09:00AM	Senti Bio Announces Additional $11.5 Million of Financing (GlobeNewswire) +5.35%
Dec-16-24 08:00AM	Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics (GlobeNewswire) -8.26%
Dec-05-24 07:00AM	Senti Bio price target raised to $12 from $10 at Chardan (TipRanks) -6.20%
Dec-03-24 08:00PM	Senti Biosciences Announces New Employment Inducement Grants (GlobeNewswire) -28.60% -7.42%
07:18AM	Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202 (TipRanks)
Dec-02-24 11:44AM	Why Is Senti Biosciences Stock Surging Over 400% On Monday? (Benzinga) +362.96%
07:10AM	Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing (GlobeNewswire)
07:02AM	Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML (GlobeNewswire)
07:00AM	Senti Bio Appoints Fran Schulz to Board of Directors (GlobeNewswire)
Nov-14-24 04:05PM	Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights (GlobeNewswire) -7.73%
Sep-03-24 08:15AM	Senti Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights (GlobeNewswire) +10.67% +10.15%
Aug-05-24 08:05AM	Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202 (GlobeNewswire) -13.11%
Jul-16-24 08:30AM	Senti Bio Announces Reverse Stock Split (GlobeNewswire)
Jul-02-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -6.59%
Jul-01-24 08:05AM	Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy (GlobeNewswire) +51.27%
Jun-25-24 08:03AM	Why Is Senti Biosciences (SNTI) Stock Up 32% Today? (InvestorPlace) +11.90%
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-13-24 08:15AM	Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia (GlobeNewswire)
May-09-24 10:55PM	SNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024 (InvestorPlace) -7.43%
04:05PM	Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights (GlobeNewswire)
Apr-30-24 08:05AM	Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire) +16.24%
Mar-21-24 10:53PM	SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023 (InvestorPlace) +6.82% -6.64%
04:05PM	Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights (GlobeNewswire)
Jan-05-24 04:05PM	Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program (GlobeNewswire) -6.15% -6.07%
Dec-26-23 11:32AM	Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate (Zacks) +5.48%
Dec-22-23 12:12PM	Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today? (Benzinga) +18.45%
06:30AM	Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia (GlobeNewswire)
Nov-13-23 04:15PM	Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates (GlobeNewswire) -16.31% -19.26%
Nov-07-23 07:54AM	Why Is Senti Biosciences (SNTI) Stock Up 140% Today? (InvestorPlace) +78.08%
Nov-06-23 04:05PM	Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China (GlobeNewswire)
Oct-31-23 09:06AM	Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-27-23 09:05AM	Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting (GlobeNewswire)
Sep-26-23 04:05PM	Senti Bio to Participate in Upcoming Conferences (GlobeNewswire)
Sep-05-23 08:30AM	Senti Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-23 09:50AM	Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:35AM	Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates (GlobeNewswire)
Aug-10-23 08:35AM	Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners (GlobeNewswire)
Jun-05-23 08:04AM	Here's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash Wisely (Simply Wall St.)
May-20-23 08:05AM	Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire)
May-09-23 04:05PM	Senti Bio Announces First Quarter 2023 Results and Pipeline Updates (GlobeNewswire) -8.00%
May-02-23 04:45PM	Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting (GlobeNewswire)
Apr-17-23 08:45AM	Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting (GlobeNewswire) -6.54%
Apr-14-23 09:00AM	Senti Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-22-23 05:09PM	Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights (GlobeNewswire)
Mar-14-23 04:35PM	Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting (GlobeNewswire) -8.63%
Feb-06-23 06:26AM	Investors in Senti Biosciences (NASDAQ:SNTI) have unfortunately lost 82% over the last year (Simply Wall St.)

Operates as a holding company whose subsidiary develops cell and gene therapies for cancer diseases

Ph.D.Dr. Timothy K. Lu M.D.

Ph.D.Dr. Kanya Rajangam M.D.

Scientific Co-FounderDr. James J. Collins Ph.D.

Chief Financial OfficerMr. Jay Cross

Scientific Co-Founder & Member of Scientific Advisory BoardDr. Wilson Wong Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNTI

Senti Biosciences Holdings Inc

Upgrade your Finviz experience